Compare TTC & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTC | NUVL |
|---|---|---|
| Founded | 1914 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Tools/Hardware | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 8.1B |
| IPO Year | 1994 | 2021 |
| Metric | TTC | NUVL |
|---|---|---|
| Price | $99.46 | $99.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | $91.00 | ★ $135.33 |
| AVG Volume (30 Days) | ★ 791.7K | 443.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.58% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $2,618,650,000.00 | N/A |
| Revenue This Year | $4.34 | N/A |
| Revenue Next Year | $4.57 | $1,064.25 |
| P/E Ratio | $31.16 | ★ N/A |
| Revenue Growth | ★ 4.53 | N/A |
| 52 Week Low | $62.34 | $55.54 |
| 52 Week High | $105.19 | $113.02 |
| Indicator | TTC | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 58.40 | 42.84 |
| Support Level | $96.54 | $98.65 |
| Resistance Level | $102.32 | $107.13 |
| Average True Range (ATR) | 2.61 | 4.05 |
| MACD | -0.64 | -0.31 |
| Stochastic Oscillator | 33.78 | 19.28 |
The Toro Co designs, manufactures, markets, and sells professional turf maintenance equipment and services; turf and agricultural irrigation systems; landscaping equipment and lighting products; snow and ice management equipment; construction equipment; and residential yard and snow thrower products. The company operates through Professional and Residential segments, with the Professional segment serving commercial, agricultural, and construction customers and generating the majority of revenue, while the Residential segment focuses on homeowners. Its products are sold through distributors, dealers, retailers, rental centers, and direct channels, with the United States as its primary revenue-generating market.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.